Mepilex XT in practice
Various wounds, including venous leg ulcers, responded well to Mepilex® XT – and the dressing effectively managed different types of wound exudate in an eight-month study.
Mepilex XT in practice: results of a study in German specialist wound care centres
Lantin A, Diegel C, Scheske J, Schmitt C, Brönner A, Jodl H. Wounds International 2015; 6(4):18-22
Table 1: Scope of data extraction from digital wound documentation system for inclusion in the analysis
|International Classification of Diseases (ICD-10)|
|Age at start of treatment|
|Signs of infection|
|Wear time/interval between dressing changes|
|Ease of dressing changes|
|Pain at dressing changes|
- During the evaluation period, 136 patients (52.2% female; 47.8% male) had wounds appropriate for treatment with Mepilex XT; wounds with no exudate were not considered suitable for treatment with the dressing.
- By week 2, a reduction in wound size was observed from a mean of 11.8cm2 (SD 20.62) at baseline to 6.6cm2 (SD 10.96) at week 2; this reduction in wound size continued into week 4 and week 6 (Figure 1).
- From baseline to week 6 of treatment, a healing rate of 31% was observed.
- Mepilex XT dressings were observed to effectively handle wound exudate, irrespective of the quantity, type and/or viscosity.
- No observation of leakage or maceration was reported throughout the study.
- Median total treatment duration with the dressing was 39 days (range 7-309 days); during this treatment duration, the median number of dressing changes per week was 3 (range 1-7).
- At dressing changes, Mepilex XT dressings were found to be easy to remove in over 85% of dressing changes.
- An overall reduction in pain severity at dressing change from baseline to week 6 was observed (pain data based on 18 patients, as other patients did not experience pain at all at dressing change).